Oxford Pharmascience Group plc (AIM: OXP) announces that, as contemplated in the Circular to Shareholders issued by the Company on 10 November 2017 and pursuant to the resolutions passed at a general meeting of shareholders on 27 November 2017, the Company has completed a subdivision of its capital whereby each Existing Share of £0.001 has been subdivided and reclassified into 1 New Share of £0.00001 and 1 Participating Deferred Share of £0.00099 (the "Subdivision").
Following the Subdivision the issued share capital of the Company consists of 1,205,661,619 New Shares of £0.00001 each and 1,205,661,619 Participating Deferred Shares of £0.00099 each.
Following the Subdivision, each Existing Shareholder's holding shall remain unchanged therefore no new share certificates will be issued. The total voting rights in the Company also remains unchanged, with 1,205,661,619 New Shares in issue. This figure may be used by Shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.
The Capital Reduction remains subject to the Court's approval and a further announcement in relation to this and the Demerger will be made in due course.
Unless otherwise indicated, capitalised terms in this announcement have the meaning given to them in the definitions appearing in the circular issued by the Company on 10 November 2017.
For further information:
|Oxford Pharmascience Group Plc|
|Chris Hill, Chief Financial Officer||+44 20 7554 5875|
|N+1 Singer (Nominated Adviser & Broker)|
|Aubrey Powell/Jen Boorer||+44 20 7496 3000|